Pharvaris NV
PHVS25.120USD
+5.290+26.68%
Cierre 07/11, 16:00（ET）Cotizaciones retrasadas 15 min
1.37BCap. mercado
PérdidaP/E TTM
Más Datos de Pharvaris NV Compañía
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Información de la empresa
Símbolo de cotizaciónPHVS
Nombre de la empresaPharvaris NV
Fecha de salida a bolsaFeb 05, 2021
Fundada en2015
Director ejecutivoMr. Berndt Modig, CPA
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
DirecciónEmmy Noetherweg 2
CiudadLEIDEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísNetherlands
Código postal2333 BK
Teléfono31712036410
Sitio Webhttps://pharvaris.com/
Símbolo de cotizaciónPHVS
Fecha de salida a bolsaFeb 05, 2021
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 15 de may
Actualizado: jue., 15 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
Accionistas
Accionistas
Proporción
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
Tipos de accionistas
Accionistas
Proporción
Private Equity
30.24%
Investment Advisor
18.67%
Venture Capital
17.96%
Hedge Fund
15.17%
Investment Advisor/Hedge Fund
7.22%
Individual Investor
6.25%
Research Firm
0.15%
Bank and Trust
0.05%
Pension Fund
0.04%
Other
4.26%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
124
52.17M
95.74%
-1.39M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
2023Q1
61
28.67M
84.75%
-3.62M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
General Atlantic LLC
7.53M
13.82%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.40M
9.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
4.41M
8.09%
+12.70K
+0.29%
Mar 31, 2025
VenBio Partners LLC
4.29M
7.87%
--
--
Mar 31, 2025
Viking Global Investors LP
3.65M
6.7%
--
--
Mar 31, 2025
EQT Life Sciences
3.56M
6.53%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
6.06%
--
--
Mar 31, 2025
VR Adviser, LLC
3.11M
5.71%
-107.41K
-3.34%
Mar 31, 2025
Deerfield Management Company, L.P.
2.02M
3.7%
--
--
Mar 31, 2025
Commodore Capital LP
1.91M
3.51%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
ALPS Medical Breakthroughs ETF
0.73%
iShares MSCI Netherlands ETF
0.1%
iShares MSCI Europe Small-Cap ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares MSCI EAFE Small-Cap ETF
0.01%
Avantis International Small Cap Equity ETF
0.01%
First Trust IPOX Europe Equity Opportunities ETF
0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.96%
ALPS Medical Breakthroughs ETF
Proporción0.73%
iShares MSCI Netherlands ETF
Proporción0.1%
iShares MSCI Europe Small-Cap ETF
Proporción0.02%
SPDR S&P International Small Cap ETF
Proporción0.02%
iShares MSCI EAFE Small-Cap ETF
Proporción0.01%
Avantis International Small Cap Equity ETF
Proporción0.01%
First Trust IPOX Europe Equity Opportunities ETF
Proporción0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
